Energy Production Defects Linked to Parkinson's Disease

A defect in the gene Pink1 may be linked to development of Parkinson's disease, a team of researchers have found

A defect in the gene Pink1 may be linked to development of Parkinson's disease, a team of researchers have found.These insights are so revolutionary that they have been published in the leading journal Science.

Vanessa Moraïs (VIB/KU Leuven):

Cerebrospinal Fluid Biomarkers Examined in Early Parkinson Disease
In a group of untreated patients compared with healthy patients, cerebrospinal fluid (CSF) levels of tau proteins, ɑ-synuclein, and β-amyloid 1-42 (Αβ1-42) appear to be associated with early stage Parkinson disease.

"Having Parkinson's disease means that you can no longer tell your own body what to do. The hope of finding a solution to this has stimulated me for many years to unravel what goes wrong in the cells of Parkinson's patients. This research is an important step forwards."

Bart De Strooper (VIB/KU Leuven):

"Parkinson's disease is one of the research focuses in our department. It gives great satisfaction that we have unraveled a molecular process responsible for the faulty energy production process in cells of Parkinson's patients. This confirms our belief that repairing the energy production in cells is a possible therapeutic strategy."

Alzheimer Disease and Parkinson Disease Do Not Appear To Share Common Genetic Risk: Study
The genetic overlap between Parkinson disease (PD) and Alzheimer disease (AD) were examined by a study.

Faulty energy production forms the basis of Parkinson's disease.

Mitochondria are cell components that produce the energy required by a cell to function. The action of these mitochondria – and therefore the energy production in cells – is disrupted in Parkinson's disease. The exact mechanism was unknown. In recent years, scientists have described various gene defects (mutations) in Parkinson's patients that result in decreased activity of the mitochondria, including a mutation in the Pink1 gene.

Tests To Predict Vulnerability To Falling In Parkinson Patients
Australian researchers have devised tests that could help identify Parkinson’s patients at risk of falling.

Molecular mechanism provides ultimate proof

Vanessa Moraïs studied the link between Pink1, mitochondria and Parkinson's disease in fruit-flies and mice with a defective Pink1 gene. These model organisms exhibited symptoms of Parkinson's disease as a result of this defect. She was able to demonstrate that the defect in Pink1 resulted in the so-called 'Complex I' – a protein complex with a crucial role in the energy production of mitochondria – not being phosphorylated adequately, resulting in decreased energy production. When Moraïs and her colleagues ensured correct phosphorylation of Complex I, the Parkinson's symptoms decreased or disappeared in mice and in patient-derived stem cell lines. The scientists thereby demonstrated that the lack of phosphorylation causes Parkinson's disease in patients with a defect Pin1 gene.

Further research in Parkinson's patients with defective Pink1 gene

This study reveals that repairing the phosphorylation of Complex I could be a treatment strategy for Parkinson's disease. The VIB scientists have already used cells from Parkinson's patients with a defective Pink1 gene to demonstrate that repairing the phosphorylation results in increased energy production. However, will this cause the symptoms of Parkinson's disease to decrease or disappear? Only tests on patients can answer this question. According to the scientists, the best strategy would be to start with the sub-group of patients with a defective Pink1 gene. But before starting clinical trials, a lot of aspects still have to be tested.

Source-Eurekalert